Novartis tries to make UK hospitals use $1000 drug

(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).

According to the U.K.'s health watchdog, Lucentis is the only drug recommended to treat the eye problem, macular degeneration.

However, the much cheaper Avastin, a cancer drug, is widely prescribed for macular degeneration, though it is not officially approved. Last year, four hospitals in southern England decided they would pay for Avastin when it was prescribed by a doctor.

Both drugs are made by Novartis.

In a statement Tuesday, Novartis said it was demanding a judicial review to make the hospitals use rather than .

Patient groups called for an independent appraisal to determine which drug should be used.

1 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

FDA panel unanimously backs Regeneron eye drug

Jun 17, 2011

(AP) -- A panel of federal health experts voted unanimously in favor of a new eye drug from Regeneron, bringing the company one step closer to competing against a blockbuster Roche drug that currently dominates the market.

Can further studies lower the cost of preserving vision?

Oct 04, 2006

The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a comp ...

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments